Memorial Sloan Kettering Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Clinical Trials
1.9k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1455 trials with phase data)• Click on a phase to view related trials
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- Conditions
- Breast Cancer
- Interventions
- Procedure: Tissue Expander (TE)Drug: Vancomycin and GentamicinDevice: Stimulan Rapid Cure
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 392
- Registration Number
- NCT07220967
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2025-10-20
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT07218250
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States
Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2025-10-20
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT07218601
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
A Study of Questionnaires in Adolescents and Young Adults With Cancer
- Conditions
- Adolescents and Young Adults With Cancer
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT07212166
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
- First Posted Date
- 2025-10-07
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT07209449
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 377
- Next
News
GemPharmatech Partners with Memorial Sloan Kettering to Accelerate Fully Human Antibody Discovery for Cancer Therapy
GemPharmatech has announced a research collaboration with Memorial Sloan Kettering Cancer Center to accelerate the discovery of fully human therapeutic antibodies using the NeoMab® transgenic mouse platform.
KEYTRUDA Plus LENVIMA Shows Durable 5-Year Survival Benefit in Advanced Endometrial Cancer
The combination of KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) demonstrated a 16.7% five-year overall survival rate in patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy alone in the Phase 3 KEYNOTE-775/Study 309 trial.
General Oncology to Present Phase 1 SHARON Trial Results for BRCA/PALB2-Mutated Cancers at ESMO 2025
General Oncology will present preliminary Phase 1 results from the SHARON trial evaluating GO-4 therapy in patients with BRCA/PALB2-mutated pancreatic and breast cancers at ESMO 2025.
SELLAS Life Sciences Announces R&D Day to Showcase Phase 3 AML Trial Results and CDK9 Inhibitor Program
SELLAS Life Sciences will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders discussing acute myeloid leukemia treatment advances and unmet medical needs.
Conflicting Results Emerge from Two Major Trials Comparing Proton Beam Therapy to IMRT for Head and Neck Cancer
Two major clinical trials presented at ASTRO 2025 reached opposite conclusions about proton beam therapy's effectiveness compared to intensity-modulated radiotherapy (IMRT) for head and neck cancer treatment.
Myriad Genetics and SOPHiA GENETICS Partner to Develop Global Liquid Biopsy Companion Diagnostic Platform
Myriad Genetics and SOPHiA GENETICS announced a strategic collaboration to develop an innovative global liquid biopsy companion diagnostic test for pharmaceutical companies.
GeneDx Strengthens Leadership Team with Key Appointments to Advance AI-Powered Precision Medicine
GeneDx appointed Lisa Gurry as Chief Business Officer to lead strategic partnerships and unlock the potential of GeneDx Infinity, the world's largest rare disease dataset with nearly one million exomes and genomes.
FORE Biotherapeutics Reports Durable Clinical Benefit with Plixorafenib in BRAF-Altered Thyroid Cancers
FORE Biotherapeutics presented Phase 1/2a data showing plixorafenib achieved a median progression-free survival of 64 months and 85.7% clinical benefit rate in MAPK inhibitor-naïve BRAF V600-mutated papillary thyroid cancer patients.
CheckMate 77T Trial Shows Perioperative Nivolumab Preserves Quality of Life in Resectable NSCLC
Perioperative nivolumab demonstrated no negative impact on health-related quality of life while reducing the risk of deterioration compared to placebo in patients with stage III N2 or non-N2 non-small cell lung cancer.
BostonGene's AI Model Identifies Five Novel Subtypes to Predict Immunotherapy Response in Kidney Cancer
BostonGene published a study in Cell Reports Medicine introducing the largest harmonized transcriptomic and clinical dataset in kidney cancer, analyzing over 3,600 patient samples.